EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Illuminating the druggable genome through patent bioactivity data

Maria P Magariños, Anna Gaulton, Eloy Félix, Tevfik Kiziloren, Ricardo Arcila, Tudor I Oprea, Andrew R Leach

PeerJ · 2023

DOI: 10.7717/peerj.15153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Maria P Magariños und 6 weiteren Autor:innen. Beteiligte Einrichtung: EMBL-EBI, Hinxton, United Kingdom. Hauptthemen laut MEDLINE: Drug Discovery, Chemistry, Pharmaceutical. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Wellcome Trust, US National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The patent literature is a potentially valuable source of bioactivity data. In this article we describe a process to prioritise 3.7 million life science relevant patents obtained from the SureChEMBL database ( https://www.surechembl.org/ ), according to how likely they were to contain bioactivity data for potent small molecules on less-studied targets, based on the classification developed by the Illuminating the Druggable Genome (IDG) project. The overall goal was to select a smaller number of patents that could be manually curated and incorporated into the ChEMBL database. Using relatively simple annotation and filtering pipelines, we have been able to identify a substantial number of patents containing quantitative bioactivity data for understudied targets that had not previously been reported in the peer-reviewed medicinal chemistry literature. We quantify the added value of such methods in terms of the numbers of targets that are so identified, and provide some specific illustrative examples. Our work underlines the potential value in searching the patent corpus in addition to the more traditional peer-reviewed literature. The small molecules found in these patents, together with their measured activity against the targets, are now accessible via the ChEMBL database.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryChemistry, PharmaceuticalDatabases, Factual

Stichwörter der Autor:innen

Bioactive compoundsDrug targetsDruggable genomePatentsSmall moleculesUnderstudied targets

Autor:innen und Institutionen

  • EMBL-EBI, Hinxton, United Kingdom.
  • Exscientia, Oxford, United Kingdom.
  • Translational informatics Division, Department of Internal Medicine, School of Medicine, University of New Mexico, Albuquerque, United States.

Förderung

  • NCI NIH HHS
  • Wellcome Trust
  • US National Institutes of Health
  • Illuminating the Druggable Genome Knowledge Management Center (IDG KMC) at the University of New Mexico
  • Novo Nordisk Foundation Center for Protein Research
  • European Bioinformatics Institute (EBI) and University of Miami
  • Member States of the European Molecular Biology Laboratory

Zitieren

APA

Magariños, M. P., Gaulton, A., Félix, E., Kiziloren, T., Arcila, R., Oprea, T. I., & Leach, A. R. (2023). Illuminating the druggable genome through patent bioactivity data. PeerJ. https://doi.org/10.7717/peerj.15153

Vancouver

Magariños MP, Gaulton A, Félix E, Kiziloren T, Arcila R, Oprea TI, et al. Illuminating the druggable genome through patent bioactivity data. PeerJ. 2023. doi:10.7717/peerj.15153

BibTeX
@article{Magarios2023,
  author = {Magariños, Maria P and Gaulton, Anna and Félix, Eloy and Kiziloren, Tevfik and Arcila, Ricardo and Oprea, Tudor I and Leach, Andrew R},
  title = {Illuminating the druggable genome through patent bioactivity data},
  journal = {PeerJ},
  year = {2023},
  doi = {10.7717/peerj.15153}
}
Kostenlos starten →